Edition:
India

Aravive Inc (ARAV.OQ)

ARAV.OQ on NASDAQ Stock Exchange Global Select Market

6.19USD
8:39pm IST
Change (% chg)

$0.38 (+6.54%)
Prev Close
$5.81
Open
$5.98
Day's High
$6.22
Day's Low
$5.98
Volume
38,109
Avg. Vol
69,271
52-wk High
$15.60
52-wk Low
$3.41

Latest Key Developments (Source: Significant Developments)

Aravive Files For Mixed Shelf Of Up To $150 Mln
Saturday, 5 Sep 2020 

Sept 4 (Reuters) - Aravive Inc ::ARAVIVE INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING.  Full Article

Aravive Inc Says Current Cash And Cash Equivalents Expected To Fund Operations Into 2022
Tuesday, 4 Aug 2020 

Aug 3 (Reuters) - Aravive Inc ::ARAVIVE REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES RECENT CORPORATE UPDATES.CURRENT CASH AND CASH EQUIVALENTS EXPECTED TO FUND OPERATIONS INTO 2022.ON-TRACK TO INITIATE PHASE 1B/2 TRIAL OF AVB-500 IN CLEAR CELL RENAL CELL CARCINOMA IN 2H 2020.Q2 LOSS PER SHARE $0.32.Q2 EARNINGS PER SHARE VIEW $-0.46 -- REFINITIV IBES DATA.  Full Article

Aravive Files For Offer And Resale Of Up To 931,098 Shares By Selling Stockholder - SEC Filing
Monday, 29 Jun 2020 

June 29 (Reuters) - Aravive Inc ::ARAVIVE INC FILES FOR OFFER AND RESALE OF UP TO 931,098 SHARES OF COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING.  Full Article

Aravive Presents Positive Data From Initial 12 Patients In Phase 1B Portion Of Its Phase 1B/2 Ovarian Cancer Study Of Avb-500 In Late Breaking Oral Presentation At European Society For Medical O
Friday, 27 Sep 2019 

Sept 27 (Reuters) - Aravive Inc ::ARAVIVE PRESENTS POSITIVE DATA FROM INITIAL 12 PATIENTS IN PHASE 1B PORTION OF ITS PHASE 1B/2 OVARIAN CANCER STUDY OF AVB-500 IN LATE BREAKING ORAL PRESENTATION AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS IN BARCELONA.ARAVIVE INC - PLANS TO REPORT DETAILED ANALYSIS ONCE DATA FROM INITIAL 30 PATIENTS ON CURRENT 10 MG/KG DOSE MATURE TOWARD END OF YEAR.ARAVIVE INC - INTENDS TO EXPLORE POTENTIAL FOR AN ACCELERATED REGULATORY PATHWAY FOR AVB-500 WITH FDA.ARAVIVE INC - AVB-500 WAS WELL TOLERATED WITH NO DOSE LIMITING TOXICITIES (DLT).ARAVIVE INC - AVB-500 WAS WELL TOLERATED WITH NO DOSE LIMITING TOXICITIES.ARAVIVE INC - PLANS TO INCORPORATE EXPOSURE-RESPONSE INFORMATION INTO THEIR PLANNED STUDIES IN CLEAR CELL RENAL CANCER & RENAL FIBROSIS TRIALS.  Full Article

Aravive Says Q2 Revenue $3.1 Million
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Aravive Inc ::ARAVIVE REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES RECENT CORPORATE UPDATES.Q2 REVENUE $3.1 MILLION.AT JUNE 30, 2019, CASH AND CASH EQUIVALENTS WERE $48.4 MILLION.QTRLY NET LOSS PER SHARE $0.27.  Full Article

Aravive Q1 Loss Per Share $0.42
Thursday, 9 May 2019 

May 8 (Reuters) - Aravive Inc ::ARAVIVE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES RECENT CORPORATE UPDATES.Q1 LOSS PER SHARE $0.42.CASH AND CASH EQUIVALENTS WERE $55.6 MILLION AS OF MARCH 31, 2019.  Full Article

Aravive Says Co May Offer Shares Of Common Stock Having Aggregate Offering Price Of Up To $20.25 Million
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Aravive Inc ::ARAVIVE-MAY OFFER/ SELL SHARES OF COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $20.25 MILLION FROM TIME TO TIME THROUGH PIPER JAFFRAY-SEC FILING.  Full Article

Aravive Reports Fourth Quarter And Full Year 2018 Financial Results
Friday, 8 Mar 2019 

March 7 (Reuters) - Aravive Inc ::ARAVIVE REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES RECENT CORPORATE UPDATES.Q4 LOSS PER SHARE $4.82.CASH AND CASH EQUIVALENTS WERE $57.0 MILLION AS OF DECEMBER 31, 2018.EXPECTS CURRENT CASH AND CASH EQUIVALENTS WILL ENABLE COMPANY TO FUND ITS OPERATING PLANS INTO END OF 2020.QTRLY TOTAL REVENUE $1.4 MILLION VERSUS $40 MILLION.  Full Article

Aravive Presents Detailed Results Of Phase 1 Clinical Trial Of AVB-S6-500 At The 2018 EORTC-NCI-AACR Symposium
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Aravive Inc ::ARAVIVE PRESENTS DETAILED RESULTS OF PHASE 1 CLINICAL TRIAL OF AVB-S6-500 AT THE 2018 EORTC-NCI-AACR SYMPOSIUM.ARAVIVE INC - PHASE 1 CLINICAL TRIAL IN HEALTHY VOLUNTEERS DEMONSTRATED THAT AVB-S6-500 WAS WELL TOLERATED WITH AN ACCEPTABLE SAFETY PROFILE..ARAVIVE INC - THERE WERE NO SERIOUS ADVERSE EVENTS (AES) AND AVB-S6-500 WAS WELL TOLERATED ACROSS ALL DOSES.  Full Article

BRIEF-Aravive Says Co Added To Russell 2000 And Russell 3000 Indexes

* ARAVIVE ADDED TO THE RUSSELL 2000® AND RUSSELL 3000® INDEXES Source text for Eikon: Further company coverage: